<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies have suggested that substance P (SP) plays a critical role in the development of <z:hpo ids='HP_0002181'>brain oedema</z:hpo> and functional deficits following traumatic brain injury and that SP receptor antagonism may improve outcome </plain></SENT>
<SENT sid="1" pm="."><plain>No studies have described such a role in <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The present study characterized the effects of the NK1 tachykinin receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, n-<z:chebi fb="9" ids="46887">acetyl</z:chebi>-<z:chebi fb="0" ids="16828,29954">L-tryptophan</z:chebi> (NAT), on blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) breakdown, <z:hpo ids='HP_0000969'>oedema</z:hpo> formation, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and functional outcome following reversible <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in rats </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> was induced using a reversible thread model of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> where occlusion was maintained for 2 h before reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Animals received either NAT or equal volume saline vehicle intravenously at 2 h post-reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo> resulted in increased perivascular SP immunoreactivity at 24 h </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of NAT significantly reduced <z:hpo ids='HP_0000969'>oedema</z:hpo> formation and <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability at 24 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and significantly improved functional outcome as assessed over 7 days </plain></SENT>
<SENT sid="7" pm="."><plain>There was no effect on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that inhibition of SP activity with a NK1 tachykinin receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> is effective in reducing cerebral <z:hpo ids='HP_0000969'>oedema</z:hpo>, <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability and functional deficits following reversible <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and may therefore represent a novel therapeutic approach to the treatment of ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>